OncoMatch/Clinical Trials/NCT07652489
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study
Official title: SPORT-SNACC: A Prospective, Multicenter, Observational Cohort Study of Surgery Plus Postoperative Radiotherapy in T4 Sinonasal Adenoid Cystic Carcinoma
Is NCT07652489 recruiting? Yes, currently enrolling (Oct 2026).
This observational study follows patients with T4 stage sinonasal adenoid cystic carcinoma (a rare cancer of the nasal cavity/sinuses) who receive standard treatment: surgery followed by postoperative radiotherapy. The main goal is to measure the 3-year progression-free survival rate (the percentage of patients alive without cancer growth or spread). We will also assess overall survival, recurrence, side effects, and quality of life. This multicenter, prospective study will provide much-needed real-world data to improve patient counseling and guide future research.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: radiotherapy
Previously untreated (no radiotherapy...)
Cannot have received: chemotherapy
Previously untreated (no...chemotherapy...)
Cannot have received: targeted therapy
Previously untreated (no...targeted therapy...)
Cannot have received: immunotherapy
Previously untreated (no...immunotherapy...)
Cannot have received: tumor resection
Previously untreated (no...tumor resection)
Lab requirements
Blood counts
anc ≥1.5×10⁹/l, platelets ≥100×10⁹/l, hb ≥90 g/l
Kidney function
cr ≤1.5×uln or crcl ≥50 ml/min
Liver function
alt/ast ≤2.5×uln, tbil ≤1.5×uln
Cardiac function
lvef ≥50%, no uncontrolled arrhythmia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07652489 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages